ClinicalTrials.gg
Active, not recruitingNCT05438329Updated May 12, 2026

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

A Phase 1/2 interventional study of DB-1305/BNT325 and Pembrolizumab in Advanced Solid Tumor, sponsored by DualityBio Inc.. Active, not recruiting at 93 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by DualityBio Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,123
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.

Read the detailed description

This is a multicenter, open-label, multiple-dose, first in human (FIH) study. The study consists of two parts: Part 1 adopts an accelerated titration at first dose level followed with classic "3+3" design to identify the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D); Part 2 is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors at the MTD/the RP2D. This study will enroll subjects with advanced/unresectable, recurrent, or metastatic malignant solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

DualityBio Inc. is the lead sponsor of 12 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of ).
  • or cytologically confirmed unresectable advanced/ solid tumors who have or progressed on or after standard systemic treatments or for which no standard treatment is available.
  • At least one as assessed by the investigator according to version 1.1 criteria.
  • Has a of ≥ 3 months.
  • Has an (ECOG) performance status (PS) of 0-1.
  • Has (LVEF) ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.
  • Has adequate organ functions within 7 days prior to Day 1 of Cycle 1.
  • Has adequate treatment prior to Day 1 of Cycle 1.
  • Is willing to provide pre-existing resected tumor samples or undergo fresh tumor for the measurement of Trop-2 level and other biomarkers if not .
  • Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.

Exclusion criteria

Exclusion Criteria:

  • Has a medical history of symptomatic congestive heart failure (CHF) ( [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.
  • Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
  • Has an average of Fredericia's formula- corrected interval (QTcF) prolongation to > 470 millisecond (ms) in males and females based on a 12-lead (ECG) in triplicate.
  • Has a medical history of non-infectious Interstitial Lung Diseases (ILD)/pneumonitis or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Has a lung-specific intercurrent illness.
  • Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals.
  • Subjects have (HIV) infection with acquired immune deficiency syndrome (AIDS) defining illness are not eligible for enrollment; However, subjects have had HIV infection with a cluster of differentiation 4 (CD4)+ T cell count > 350 cells/µL and no history of an AIDS-defining illness are eligible for entry.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,123 participants (estimated)

Study arms

  • Experimental
    DB-1305/BNT325 Dose Level 1

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 1

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 2

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 2

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 3

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 3

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 4

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 4

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 5

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 5

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 6

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 6

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 7

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 7

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 in combination with pembrolizumab

    Enrolled subjects will receive DB-1305/BNT325 in combination with pembrolizumab

    Drug: DB-1305/BNT325 · Combination Product: Pembrolizumab

  • Experimental
    DB-1305/BNT325 Dose Expansion 1

    subjects with Non-Small Cell Lung Cancer (NSCLC) with actionable genetic alterations (AGAs) who will receive DB-1305/BNT325 on either dose level 1 or dose level 2

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 2

    Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on either dose level 1 or dose level 2

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 3

    Enrolled subjects with OC who will receive DB-1305/BNT325 on either dose level 1 or dose level 2

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 4

    Enrolled subjects with BC who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 5

    Enrolled subjects with Triple-Negative Breast Cancer (TNBC) who have progressed on or after standard systemic treatments and without prior treatment of sacituzumab govitecan who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 6

    Enrolled subjects with TNBC with treatment failure on sacituzumab govitecan who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 7

    Enrolled subjects with EC who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 8

    Enrolled subjects with malignant mesothelioma will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 9

    Enrolled subjects with Cervical Cancer (CC) who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    Experimental: DB-1305/BNT325 Dose Expansion 10

    Enrolled subjects with pancreatic cancer who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion 11

    Enrolled subjects with Castration-Resistant Prostate Cancer (CRPC) who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion PB1

    Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with pembrolizumab

    Drug: DB-1305/BNT325 · Combination Product: Pembrolizumab

  • Experimental
    Experimental: DB-1305/BNT325 Dose Level 8

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 8

    Drug: DB-1305/BNT325

  • Experimental
    Experimental: DB-1305/BNT325 in combination with BNT327

    Enrolled subjects will receive DB-1305/BNT325 in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

  • Experimental
    Experimental: DB-1305/BNT325 Dose Expansion PM1

    Enrolled subjects with NSCLC without AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

  • Experimental
    Experimental: DB-1305/BNT325 Dose Expansion PM2

    Enrolled subjects with NSCLC with AGAs who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

  • Experimental
    Experimental: DB-1305/BNT325 Dose Expansion PM3

    Enrolled subjects with CC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

  • Experimental
    Experimental: DB-1305/BNT325 Dose Expansion PM4

    Enrolled subjects with OC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

  • Experimental
    Experimental: DB-1305/BNT325 Dose Expansion PM5

    Enrolled subjects with TNBC who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

  • Experimental
    DB-1305/BNT325 Dose Expansion 12

    Enrolled subjects with head and neck cancer who will receive DB-1305/BNT325 on a selected dose level (RP2D)

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Level 9

    Enrolled subjects will receive DB-1305/BNT325 at Dose Level 9

    Drug: DB-1305/BNT325

  • Experimental
    DB-1305/BNT325 Dose Expansion PM6

    Enrolled subjects with NSCLC without AGA who will receive DB-1305/BNT325 on a selected dose level in combination with BNT327

    Drug: DB-1305/BNT325 · Drug: BNT327

Interventions

  • DrugDB-1305/BNT325

    Administered Injection of Vein (I.V.)

    Also known as: DB-1305/BNT325 for Injection

  • Combination productPembrolizumab

    Administered I.V.

  • DrugBNT327

    Administered I.V.

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

    Percentage of participants in Part 1 with DLTs

    Time frame: up to 28 days after Cycle 1 Day 1

  2. Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.

    Percentage of participants with TEAEs in Part 1 graded according to NCI CTCAE v5.0

    Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.

  3. Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.

    Percentage of Participants with SAEs in Part 1 graded according to NCI CTCAE v5.0

    Time frame: Up 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.

  4. Maximum Tolerated Dose (MTD) of DB-1305/BNT325

    MTD on the data collected during Part 1

    Time frame: At the end of Cycle 1 (each cycle is up to 21 days)

  5. Phase 1: RP2D of DB-1305/BNT325

    RP2D of DB-1305/BNT325 based on the data collected during Part 1

    Time frame: From first study treatment administration until the initiation of Phase 2a, approximately up to 12 months.

  6. Phase 2a: Percentage of Participants with TEAEs as assessed by CTCAE v5.0.

    Percentage of participants with TEAEs in Part 2 graded according to NCI CTCAE v5.0 (secondary outcome measure in cohort 3)

    Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.

  7. Phase 2a: Percentage participants with SAEs as assessed by CTCAE v5.0.

    Percentage of participants with SAEs in Part 2 graded according to NCI CTCAE v5.0 (secondary outcome measure in cohort 3)

    Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.

  8. Phase 2a: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    The percentage of subjects who had a best response rating of CR and PR

    Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.

Secondary outcomes

  1. Phase 1: ORR will be determined from tumor assessments by investigator per RECIST 1.1

    Phase 1: ORR will be determined from tumor assessments by investigator per RECIST 1.1

    Time frame: with 8 cycles (each cycle is up to 21 days)

  2. Phase 1 & Phase 2a: duration of response (DoR) will be determined from tumor assessments by investigator per RECIST 1.1

    Phase 1 \& Phase 2a: duration of response (DoR) will be determined from tumor assessments by investigator (by BICR in cohort 3 in Phase 2a) per RECIST 1.1

    Time frame: with 8 cycles (each cycle is up to 21 days)

  3. Phase 1 & Phase 2a: disease-control rate (DCR)

    Phase 1 \& Phase 2a: disease-control rate (DCR)

    Time frame: with 8 cycles (each cycle is up to 21 days)

  4. Phase 1 & Phase 2a: time to response (TTR)

    Phase 1 \& Phase 2a: time to response (TTR)

    Time frame: with 8 cycles (each cycle is up to 21 days)

  5. Phase 1 & Phase 2a: progression free survival (PFS) will be determined from tumor assessments by investigator per RECIST 1.1

    Phase 1 \& Phase 2a: progression free survival (PFS) will be determined from tumor assessments by investigator (by BICR in cohort 3 in Phase 2a) per RECIST 1.1

    Time frame: with 8 cycles (each cycle is up to 21 days)

  6. Phase 1 & Phase 2a: overall survival (OS)

    Phase 1 \& Phase 2a: overall survival (OS)

    Time frame: with 8 cycles (each cycle is up to 21 days)

  7. Phase 1 & Phase 2a: Pharmacokinetic parameters: (the area under the concentration-time curve from the time zero to the last quantifiable concentration [AUC0-last] of DB-1305/BNT325

    Phase 1 \& Phase 2a: Pharmacokinetic parameters: (the area under the concentration-time curve from the time zero to the last quantifiable concentration \[AUC0-last\] of DB-1305/BNT325

    Time frame: within 8 cycles (each cycle is up to 21 days)

  8. Phase 1 & Phase 2a: Pharmacokinetic parameters: the area under the concentration-time curve from time 0 to tau [AUC0-tau] of DB-1305/BNT325

    Phase 1 \& Phase 2a: Pharmacokinetic parameters: the area under the concentration-time curve from time 0 to tau \[AUC0-tau\] of DB-1305/BNT325

    Time frame: within 8 cycles (each cycle is up to 21 days)

  9. Phase 1 & Phase 2a: peak observed concentration [Cmax] of DB-1305/BNT325

    Phase 1 \& Phase 2a: peak observed concentration \[Cmax\] of DB-1305/BNT325

    Time frame: within 8 cycles (each cycle is up to 21 days)

  10. Phase 1 & Phase 2a: Pharmacokinetic parameters: time to Cmax [Tmax] of DB-1305/BNT325

    Phase 1 \& Phase 2a: Pharmacokinetic parameters: time to Cmax \[Tmax\] of DB-1305/BNT325

    Time frame: within 8 cycles (each cycle is up to 21 days)

  11. Phase 1 & Phase 2a: Pharmacokinetic parameters: trough concentration [Ctrough] of DB-1305/BNT325

    Phase 1 \& Phase 2a: Pharmacokinetic parameters: trough concentration \[Ctrough\] of DB-1305/BNT325

    Time frame: within 8 cycles (each cycle is up to 21 days)

  12. Phase 1 & Phase 2a: anti-drug antibody (ADA) prevalence: the proportion of subjects who are ADA positive at any point in time (at baseline and post-baseline). ADA incidence: the proportion of subjects having treatment-emergent ADA.

    Phase 1 \& Phase 2a: anti-drug antibody (ADA) prevalence of DB-1305: the proportion of subjects who are ADA positive at any point in time (at baseline and post-baseline). ADA incidence of DB-1305: the proportion of subjects having treatment-emergent ADA.

    Time frame: within 8 cycles (each cycle is up to 21 days)

07

Study locations

93 sites
  • Site 139
    Bullhead City, Arizona 86442, United States
  • Site 103
    Cerritos, California 90703, United States
  • Site 136
    La Jolla, California 92093, United States
  • Site 127
    Los Angeles, California 90027, United States
  • Site 133
    Los Angeles, California 90067, United States
  • Site 108
    Los Angeles, California 90404, United States
  • Site 131
    Washington D.C., District of Columbia 20007, United States
  • Site 122
    Coral Springs, Florida 33065, United States
  • Site 142
    Hialeah, Florida 33013, United States
  • Site 114
    Margate, Florida 33063, United States
  • Site 120
    Miami, Florida 33133, United States
  • Site 126
    Ocala, Florida 34474, United States
  • Site 140
    Orange City, Florida 32763, United States
  • Site 109
    Plantation, Florida 33322, United States
  • Site 141
    St. Petersburg, Florida 33709, United States
  • Site 117
    Tamarac, Florida 33321, United States
  • Site 111
    Honolulu, Hawaii 96813, United States
  • Site 134
    Chicago, Illinois 60611, United States
  • Site 124
    Dearborn, Michigan 48126, United States
  • Site 106
    Detroit, Michigan 48201, United States
  • Site 125
    Royal Oak, Michigan 48073, United States
  • Site 129
    Las Vegas, Nevada 89106, United States
  • Site 160
    Mineola, New York 11501, United States
  • Site 116
    New York, New York 10016, United States
  • Site 102
    New York, New York 10065, United States
  • Site 130
    Westbury, New York 11590, United States
  • Site 121
    Wilson, North Carolina 27895, United States
  • Site 101
    Canton, Ohio 44718, United States
  • Site 132
    Cincinnati, Ohio 45219, United States
  • Site 118
    Oklahoma City, Oklahoma 73104, United States
  • Site 123
    Philadelphia, Pennsylvania 19107, United States
  • Site 112
    Pittsburgh, Pennsylvania 15224, United States
  • Site 105
    Nashville, Tennessee 37203, United States
  • Site 110
    Arlington, Texas 76017, United States
  • Site 104
    Houston, Texas 77030, United States
  • Site 115
    Houston, Texas 77074, United States
  • Site 119
    Tyler, Texas 75701, United States
  • Site 107
    Fairfax, Virginia 22031, United States
  • Site 135
    Falls Church, Virginia 19107, United States
  • Site 128
    Tacoma, Washington 98405, United States
  • Site 138
    Tacoma, Washington 98405, United States
  • Site 137
    Sheboygan, Wisconsin 53081, United States
  • Site 211
    Bengbu, Anhui 233099, China
  • Site 217
    Hefei, Anhui 230031, China
  • Site 213
    Fuzhou, Fujian 350001, China
  • Site 214
    Fuzhou, Fujian 350014, China
  • Site 226
    Lanzhou, Gansu 730050, China
  • Site 245
    Dongguan, Guangdong 523059, China
  • Site 219
    Guangzhou, Guangdong 510080, China
  • Site 234
    Guangzhou, Guangdong 510080, China
  • Site 225
    Guangzhou, Guangdong 510120, China
  • Site 221
    Guigang, Guangxi 537100, China
  • Site 235
    Nanning, Guangxi 530021, China
  • Site 209
    Nanning, Guangxi 531200, China
  • Site 227
    Haikou, Hainan 570102, China
  • Site 208
    Baoding, Hebei 071030, China
  • Site 243
    Chengde, Hebei 067000, China
  • Site 223
    Harbin, Heilongjiang 150081, China
  • Site 239
    Anyang, Henan 455000, China
  • Site 202
    Zhengzhou, Henan 450000, China
  • Site 205
    Wuhan, Hubei 430021, China
  • Site 253
    Wuhan, Hubei 430079, China
  • Site 231
    Changsha, Hunan 410011, China
  • Site 224
    Changsha, Hunan 410013, China
  • Site 252
    Changsha, Hunan 410013, China
  • Site 233
    Nanjing, Jiangsu 210009, China
  • Site 215
    Ganzhou, Jiangxi 341000, China
  • Site 246
    Ganzhou, Jiangxi 341001, China
  • Site 242
    Nanchang, Jiangxi 330029, China
  • Site 250
    Nanchang, Jiangxi 330029, China
  • Site 229
    Nanchang, Jiangxi 330038, China
  • Site 201
    Changchun, Jilin 130012, China
  • Site 249
    Changchun, Jilin 130021, China
  • Site 248
    Yanbian, Jilin 133000, China
  • Site 210
    Shenyang, Liaoning 110042, China
  • Site 241
    Xi'an, Shaanxi 710100, China
  • Site 216
    Jinan, Shandong 250117, China
  • Site 237
    Jining, Shandong 272007, China
  • Site 247
    Linyi, Shandong 276034, China
  • Site 212
    Linyi, Shandong 276304, China
  • Site 236
    Qingdao, Shandong 266035, China
  • Site 207
    Shanghai, Shanghai Municipality 201315, China
  • Site 238
    Taiyuan, Shanxi 030001, China
  • Site 206
    Chengdu, Sichuan 611135, China
  • Site 203
    Tianjin, Tianjin Municipality 300060, China
  • Site 232
    Ürümqi, Xinjiang 830000, China
  • Site 240
    Kunming, Yunnan 650118, China
  • Site 222
    Hangzhou, Zhejiang 310022, China
  • Site 220
    Taizhou, Zhejiang 317004, China
  • Site 228
    Wenzhou, Zhejiang 325015, China
  • Site 230
    Chongqing, 400030, China
  • Site 244
    Shanghai, 200123, China
  • Site 113
    Mayagüez, Puerto Rico 00682, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 29, 2022
StartActual
Jul 19, 2022
Primary completionEst.
Aug 13, 2027
CompletionEst.
Sep 10, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05438329
Lead sponsor
DualityBio Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Jul 19, 2022
Primary completion
Aug 13, 2027 (estimated)
Completion
Sep 10, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Lily Hu
study director · DualityBio Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion